Statin use and prostate cancer risk in a large population-based setting

Denise M. Boudreau, Onchee Yu, Diana S M Buist, Diana L Miglioretti

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: Statins are a commonly used cholesterol-lowering drug, which also have the potential to affect cancer risk and progression. Results from previous studies offer mixed conclusions. Methods: To evaluate the relation between statin use and prostate cancer risk, we conducted a retrospective cohort study during 1 January 1990 to 31 August 2005 among men 45-79 years receiving care within Group Health, an integrated healthcare delivery system. Information on statin use and covariates were obtained from health plan databases. We identified incident prostate cancer cases through the Surveillance, Epidemiology, and End Results cancer registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for prostate cancer among statin users compared to non-users. Results: Among 83,372 men studied, median follow-up time was 5.7 years and 2,532 prostate cancer cases were identified. About 14.4% used statins over the study period and median duration of use was 3.3 years. Compared to non-users, hydrophobic statin users had a reduced risk of prostate cancer (HR = 0.79; 95% CI, 0.66-0.94), and results are suggestive of a reduced risk among ever users of statins (HR = 0.88; 95% CI, 0.76-1.02) and hydrophilic statin users (HR = 0.67; 95% CI, 0.33-1.34). There was no trend in risk by duration of statin use, and no association between statin use and cancer aggressiveness, stage, or grade. Conclusion: Overall, this study does not support an associated between statin use and prostate cancer but a reduced risk cannot be ruled out.

Original languageEnglish (US)
Pages (from-to)767-774
Number of pages8
JournalCancer Causes and Control
Volume19
Issue number7
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Prostatic Neoplasms
Population
Confidence Intervals
Integrated Delivery of Health Care
Delivery of Health Care
Neoplasms
Health
Proportional Hazards Models
Registries
Epidemiology
Cohort Studies
Retrospective Studies
Cholesterol

Keywords

  • Cancer
  • HMG-CoA reductase inhibitors
  • Lipid lowering drugs
  • Prostate cancer
  • Statins

ASJC Scopus subject areas

  • Oncology
  • Epidemiology
  • Cancer Research

Cite this

Statin use and prostate cancer risk in a large population-based setting. / Boudreau, Denise M.; Yu, Onchee; Buist, Diana S M; Miglioretti, Diana L.

In: Cancer Causes and Control, Vol. 19, No. 7, 09.2008, p. 767-774.

Research output: Contribution to journalArticle

Boudreau, Denise M. ; Yu, Onchee ; Buist, Diana S M ; Miglioretti, Diana L. / Statin use and prostate cancer risk in a large population-based setting. In: Cancer Causes and Control. 2008 ; Vol. 19, No. 7. pp. 767-774.
@article{50cb3637eb4e49e7a5f0f276f53d27af,
title = "Statin use and prostate cancer risk in a large population-based setting",
abstract = "Background: Statins are a commonly used cholesterol-lowering drug, which also have the potential to affect cancer risk and progression. Results from previous studies offer mixed conclusions. Methods: To evaluate the relation between statin use and prostate cancer risk, we conducted a retrospective cohort study during 1 January 1990 to 31 August 2005 among men 45-79 years receiving care within Group Health, an integrated healthcare delivery system. Information on statin use and covariates were obtained from health plan databases. We identified incident prostate cancer cases through the Surveillance, Epidemiology, and End Results cancer registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95{\%} confidence intervals (CI) for prostate cancer among statin users compared to non-users. Results: Among 83,372 men studied, median follow-up time was 5.7 years and 2,532 prostate cancer cases were identified. About 14.4{\%} used statins over the study period and median duration of use was 3.3 years. Compared to non-users, hydrophobic statin users had a reduced risk of prostate cancer (HR = 0.79; 95{\%} CI, 0.66-0.94), and results are suggestive of a reduced risk among ever users of statins (HR = 0.88; 95{\%} CI, 0.76-1.02) and hydrophilic statin users (HR = 0.67; 95{\%} CI, 0.33-1.34). There was no trend in risk by duration of statin use, and no association between statin use and cancer aggressiveness, stage, or grade. Conclusion: Overall, this study does not support an associated between statin use and prostate cancer but a reduced risk cannot be ruled out.",
keywords = "Cancer, HMG-CoA reductase inhibitors, Lipid lowering drugs, Prostate cancer, Statins",
author = "Boudreau, {Denise M.} and Onchee Yu and Buist, {Diana S M} and Miglioretti, {Diana L}",
year = "2008",
month = "9",
doi = "10.1007/s10552-008-9139-4",
language = "English (US)",
volume = "19",
pages = "767--774",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "7",

}

TY - JOUR

T1 - Statin use and prostate cancer risk in a large population-based setting

AU - Boudreau, Denise M.

AU - Yu, Onchee

AU - Buist, Diana S M

AU - Miglioretti, Diana L

PY - 2008/9

Y1 - 2008/9

N2 - Background: Statins are a commonly used cholesterol-lowering drug, which also have the potential to affect cancer risk and progression. Results from previous studies offer mixed conclusions. Methods: To evaluate the relation between statin use and prostate cancer risk, we conducted a retrospective cohort study during 1 January 1990 to 31 August 2005 among men 45-79 years receiving care within Group Health, an integrated healthcare delivery system. Information on statin use and covariates were obtained from health plan databases. We identified incident prostate cancer cases through the Surveillance, Epidemiology, and End Results cancer registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for prostate cancer among statin users compared to non-users. Results: Among 83,372 men studied, median follow-up time was 5.7 years and 2,532 prostate cancer cases were identified. About 14.4% used statins over the study period and median duration of use was 3.3 years. Compared to non-users, hydrophobic statin users had a reduced risk of prostate cancer (HR = 0.79; 95% CI, 0.66-0.94), and results are suggestive of a reduced risk among ever users of statins (HR = 0.88; 95% CI, 0.76-1.02) and hydrophilic statin users (HR = 0.67; 95% CI, 0.33-1.34). There was no trend in risk by duration of statin use, and no association between statin use and cancer aggressiveness, stage, or grade. Conclusion: Overall, this study does not support an associated between statin use and prostate cancer but a reduced risk cannot be ruled out.

AB - Background: Statins are a commonly used cholesterol-lowering drug, which also have the potential to affect cancer risk and progression. Results from previous studies offer mixed conclusions. Methods: To evaluate the relation between statin use and prostate cancer risk, we conducted a retrospective cohort study during 1 January 1990 to 31 August 2005 among men 45-79 years receiving care within Group Health, an integrated healthcare delivery system. Information on statin use and covariates were obtained from health plan databases. We identified incident prostate cancer cases through the Surveillance, Epidemiology, and End Results cancer registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for prostate cancer among statin users compared to non-users. Results: Among 83,372 men studied, median follow-up time was 5.7 years and 2,532 prostate cancer cases were identified. About 14.4% used statins over the study period and median duration of use was 3.3 years. Compared to non-users, hydrophobic statin users had a reduced risk of prostate cancer (HR = 0.79; 95% CI, 0.66-0.94), and results are suggestive of a reduced risk among ever users of statins (HR = 0.88; 95% CI, 0.76-1.02) and hydrophilic statin users (HR = 0.67; 95% CI, 0.33-1.34). There was no trend in risk by duration of statin use, and no association between statin use and cancer aggressiveness, stage, or grade. Conclusion: Overall, this study does not support an associated between statin use and prostate cancer but a reduced risk cannot be ruled out.

KW - Cancer

KW - HMG-CoA reductase inhibitors

KW - Lipid lowering drugs

KW - Prostate cancer

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=48149114863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48149114863&partnerID=8YFLogxK

U2 - 10.1007/s10552-008-9139-4

DO - 10.1007/s10552-008-9139-4

M3 - Article

C2 - 18322813

AN - SCOPUS:48149114863

VL - 19

SP - 767

EP - 774

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 7

ER -